China Human Papillomavirus (HPV) Vaccine Market Report 2022 to 2030

China Human Papillomavirus (HPV) Vaccine Market Analysis

$ 3999

China Human Papillomavirus (HPV) vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for HPV vaccines is mainly being driven by the rising need for prevention of these infections as well as the rising prevalence of human papillomavirus (HPV)-related malignancies of the anus, vulva, vagina, penis, and oropharynx. Some of the key players in this market are Xenetic Biosciences, Inc., Bharat Biotech., AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson, Serum Institute of India Pvt. Ltd, Inovio Pharmaceuticals, Inc, Novartis AG, Sanofi, Merck & Co., Inc.

ID: IN10CNPH304 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Saloni Shah

Buy Now

China Human Papillomavirus (HPV) Vaccine Market Analysis Summary

China Human Papillomavirus (HPV) Vaccine Market is valued at around $342.3 Mn in 2022 and is projected to reach $987.9 Mn by 2030, exhibiting a CAGR of 14.17% during the forecast period 2023-2030.

Most occurrences of cervical cancer are associated with the human papillomavirus (HPV), a sexually transmitted infection. The broad use of the HPV vaccine should reduce the incidence of cervical cancer and other HPV-related cancers worldwide. The majority of cases of cervical cancer are brought on by different HPV strains, which are transferred during sexual activity. Both girls and boys can receive the HPV vaccine Gardasil 9, which has been given the green light by the American Food and Drug Administration. By giving this vaccine before girls or women are exposed to the virus, the majority of cases of cervical cancer can be prevented. This vaccine also guards against vaginal and vulvar cancer. Additionally, the immunisation protects both men and women from genital warts, anal cancer, and mouth, throat, head, and neck malignancies. According to the Centers for Disease Control and Prevention (CDC), the HPV vaccine should be given to both boys and girls between the ages of 11 and 12. It can be given to children as young as nine. Both boys and girls should receive the vaccine before engaging in sexual activity and becoming exposed to HPV. Early vaccination is not linked to an earlier initiation of sexual activity, according to studies. The market for HPV vaccines is mainly being driven by the rising need for prevention of these infections as well as the rising prevalence of human papillomavirus (HPV)-related malignancies of the anus, vulva, vagina, penis, and oropharynx. Some of the key players in this market are Xenetic Biosciences, Inc., Bharat Biotech., AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson, Serum Institute of India Pvt. Ltd, Inovio Pharmaceuticals, Inc, Novartis AG, Sanofi, Merck & Co., Inc.

Market Dynamics

Market Growth Drivers

One of the most important and major market drivers is the efficacy and protection provided by HPV vaccines to decrease the negative effects associated with such infections. As manufacturers have developed new vaccines for immunisation, a change in vaccination practises and attitudes has been observed around the world in recent years. The acceptance and uptake of HPV vaccinations may have increased as a result. Both bivalent and polyvalent vaccinations are effective and safe in preventing HPV-related illnesses and cancer, according to clinical research. In addition, it is projected that rising cervical cancer rates in various nations may boost sales of the human papillomavirus vaccine.

Market Restraints

Despite an increase in demand for HPV vaccinations due to their effectiveness in lowering infections, market growth is anticipated to be constrained by the makers' limited product options. Due to the delayed progress of the vaccine's development, only a small number of products will be released onto the market. The HPV vaccine market is anticipated to be smaller despite the potential pipeline candidates in the row.

Competitive Landscape

Key Players

Merck & Co., Inc.
GlaxoSmithKline plc (GSK)
Pfizer Inc.
Novartis AG
Johnson & Johnson
AstraZeneca plc
Serum Institute of India
Bharat Biotech International Ltd.
Moderna, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

sexy Human Papillomavirus (HPV) Vaccine Market Segmentation

By Disease Indication

Cervical Cancer
Anal Cancer
Vulvar and Vaginal Cancer
Penile Cancer
Oropharyngeal Cancer
Others

By Industry

Public and Private Alliances
Government Entities
Physicians
Others

By End Users

Hospitals
Specialty Clinics
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.